Patients with metastatic breast cancer can predict their response to HER2-targeted therapy using whole-body PET/CT.

Published Date: 13 Nov 2023

A novel imaging agent called 68Ga-ABY-025 has the ability to forecast the early metabolic reaction to treatment that targets the human epidermal growth factor receptor 2 (HER2).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Dasatinib Fails to Improve Outcomes in CBF-AML

2.

Discovery of estrogen receptor 'switches' may aid breast cancer treatment

3.

Medical debt in collections persists after cancer diagnosis

4.

Childhood cancer survivors face new health problems later in life, study shows

5.

A Lot Can Be Said About You by Including Yourself in Photos.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot